204 related articles for article (PubMed ID: 30990564)
1. Novel Targets and Precision Medicine for Prostate Cancer-Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer.
Considine B; Petrylak DP
Oncology (Williston Park); 2019 Apr; 33(4):128-31. PubMed ID: 30990564
[TBL] [Abstract][Full Text] [Related]
2. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
3. Olaparib Targets Some Advanced Prostate Cancers.
Cancer Discov; 2016 Jan; 6(1):OF1. PubMed ID: 26658963
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in DNA Repair Pathway and Its Application in Personalized Care of Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Xu C; Mao S; Jiang H
Methods Mol Biol; 2020; 2204():75-89. PubMed ID: 32710316
[TBL] [Abstract][Full Text] [Related]
5. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
Dhawan M; Ryan CJ; Ashworth A
Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
[TBL] [Abstract][Full Text] [Related]
6. DNA Repair in Prostate Cancer: Biology and Clinical Implications.
Mateo J; Boysen G; Barbieri CE; Bryant HE; Castro E; Nelson PS; Olmos D; Pritchard CC; Rubin MA; de Bono JS
Eur Urol; 2017 Mar; 71(3):417-425. PubMed ID: 27590317
[TBL] [Abstract][Full Text] [Related]
7. [The PROfound study or the arrival of personalised medicine in the treatment of prostate cancer].
Houédé N
Bull Cancer; 2021 May; 108(5):448. PubMed ID: 33722378
[No Abstract] [Full Text] [Related]
8. Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.
Beltran H; Antonarakis ES; Morris MJ; Attard G
Am Soc Clin Oncol Educ Book; 2016; 35():131-41. PubMed ID: 27249694
[TBL] [Abstract][Full Text] [Related]
9. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
Karzai F; VanderWeele D; Madan RA; Owens H; Cordes LM; Hankin A; Couvillon A; Nichols E; Bilusic M; Beshiri ML; Kelly K; Krishnasamy V; Lee S; Lee MJ; Yuno A; Trepel JB; Merino MJ; Dittamore R; Marté J; Donahue RN; Schlom J; Killian KJ; Meltzer PS; Steinberg SM; Gulley JL; Lee JM; Dahut WL
J Immunother Cancer; 2018 Dec; 6(1):141. PubMed ID: 30514390
[TBL] [Abstract][Full Text] [Related]
10. Stratifying prostate patients for olaparib.
Cancer Discov; 2015 Jun; 5(6):568-9. PubMed ID: 25904654
[TBL] [Abstract][Full Text] [Related]
11. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
12. Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment.
Schweizer MT; Cheng HH; Nelson PS; Montgomery RB
J Clin Oncol; 2020 Nov; 38(32):3740-3742. PubMed ID: 32897829
[No Abstract] [Full Text] [Related]
13. Towards precision oncology in advanced prostate cancer.
Ku SY; Gleave ME; Beltran H
Nat Rev Urol; 2019 Nov; 16(11):645-654. PubMed ID: 31591549
[TBL] [Abstract][Full Text] [Related]
14. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
[TBL] [Abstract][Full Text] [Related]
15. Precision medicine becomes reality-tumor type-agnostic therapy.
Yan L; Zhang W
Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
[TBL] [Abstract][Full Text] [Related]
16. Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer.
Modena A; Iacovelli R; Scarpa A; Brunelli M; Ciccarese C; Fantinel E; Bimbatti D; Massari F; Martignoni G; Tortora G
Target Oncol; 2016 Oct; 11(5):569-577. PubMed ID: 27402433
[TBL] [Abstract][Full Text] [Related]
17. Genetic biomarkers to guide poly(ADP-ribose) polymerase inhibitor precision treatment of prostate cancer.
Varnai R; Sipeky C
Pharmacogenomics; 2020 Oct; 21(15):1101-1115. PubMed ID: 33021139
[TBL] [Abstract][Full Text] [Related]
18. Treatment strategies for DNA repair-deficient prostate cancer.
Teply BA; Antonarakis ES
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):889-898. PubMed ID: 28573914
[TBL] [Abstract][Full Text] [Related]
19. Exceptional Response to Pembrolizumab in a Patient With Castration-Resistant Prostate Cancer With Pancytopenia From Myelophthisis.
Vlachostergios PJ; Geyer JT; Miller J; Kosloff R; Beltran H; Tagawa ST
J Oncol Pract; 2019 Jun; 15(6):343-345. PubMed ID: 30964731
[No Abstract] [Full Text] [Related]
20. Loose Regulatory Standards Portend a New Era of Imprecision Oncology.
Khaki AR
Cancer Invest; 2021 Feb; 39(2):120-123. PubMed ID: 33290099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]